Typhoid Vaccine Acceleration Consortium (TyVAC)
The Typhoid Vaccine Acceleration Consortium (TyVAC) aims to accelerate the use of typhoid conjugate vaccine (TCV) in endemic settings and support country decision-making. We employ a complementary suite of activities to optimize the use – and ultimately public health impact – of TCVs while simultaneously supporting the long-term sustainability of TCV programs and collaborative partnerships.
Typhoid, a serious enteric fever caused by Salmonella Typhi, is spread through contaminated food and water. While largely eliminated in industrialized countries, typhoid continues to be a substantial public health issue in Asia, sub-Saharan Africa, and parts of Latin America and the Middle East.
The Global Burden of Disease estimates typhoid caused more than 9 million infections and more than 110,000 deaths globally in 2019, with young children and adolescents aged 2 to 15 years disproportionately impacted. Though treatable with antibiotics, the number of cases resistant to available antibiotics is increasing.
There are currently two TCVs, Typbar TCV® and TYPHIBEV®, approved and recommended for use by the World Health Organization. A single dose of TCV is safe, well-tolerated, and efficacious for at least four years, including in children younger than 2 years of age.
Engage with countries and local partners, provide assistance while fostering country ownership, strengthen local capacity, support decision-making, and enhance collaboration.
Coordinate with the typhoid community, maintain momentum and attention on typhoid as a global health priority, and ensure widespread and sustainable TCV introductions.
Generate new evidence related to typhoid disease burden, antimicrobial resistance, cost-effectiveness/cost-of-illness, and regional data on TCVs.
Advocate with partners for an integrated approach that includes vaccines in combination with improved water, sanitation, and hygiene (WASH).
Project Director, Kathleen Neuzil, is the Myron M. Levine Professor in Vaccinology, Professor of Medicine and Pediatrics, and the Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine. She is an internationally recognized research scientist and advocate in the field of vaccinology and has led TyVAC since its inception in 2017. She has more than 300 scientific publications on vaccines and infectious diseases. Dr. Neuzil is a member of the World Health Organization Strategic Advisory Group of Experts on Immunization and the prestigious National Academy of Medicine.
- TCV is highly immunogenic in Burkinabe children 30-35 months post-vaccination.
- Exploring the link between climate change and WASH: insights from the World Water Week 2023.
- Caterpillars and typhoid in Democratic Republic of the Congo.
- Risk of spreading typhoid in extreme weather through contaminated water.
- Drug-resistant typhoid: what we need to know.
- Vaccination is a community achievement: the faces of a typhoid conjugate vaccine campaign in Fiji.
- Improvements in WASH are needed to protect communities.
- As monsoon rains intensify, so does typhoid risk in India.
- Vaccination toward elimination: protecting communities in Fiji's Northern Division from typhoid.
- Treating typhoid costs more than money.
- Phone: 410-706-5328
- Email: TyVAC@som.umaryland.edu
Visit the Take on Typhoid website for additional information and to sign up for our newsletter!